ABSTRACT
Asthma is now considered primarily an inflammatory disease in which bronchospasm occurs secondary to airway inflammation. Management strategies include the use of inhaled anti-inflammatory agents, notably inhaled corticosteroids and cromolyn. Mild intermittent asthma may be treated with inhaled bronchodilators. Moderate asthma should be treated with an inhaled anti-inflammatory agent in addition to an inhaled beta agonist. If symptoms persist, an oral bronchodilator (either a beta-adrenergic agonist or theophylline) should be added. Therapy for severe asthma includes combinations of the foregoing medications, with the possible addition of oral corticosteroids. Other aspects of management include the use of a spacer device with inhaler therapy, control of concomitant allergies and triggering factors such as chronic sinusitis, tobacco smoke and gastroesophageal reflux, and home use of a portable peak flow meter to monitor the disease.
Subject(s)
Asthma/drug therapy , Clinical Protocols/standards , Adrenal Cortex Hormones/therapeutic use , Adrenergic beta-Agonists/therapeutic use , Adult , Asthma/diagnosis , Asthma/etiology , Bronchodilator Agents/therapeutic use , Cromolyn Sodium/therapeutic use , Decision Trees , Forced Expiratory Volume , Humans , National Institutes of Health (U.S.) , Peak Expiratory Flow Rate , Severity of Illness Index , Treatment Outcome , United StatesSubject(s)
Attitude to Health , Diet , Drug Evaluation , Adult , Arthritis, Rheumatoid/drug therapy , Aspirin/therapeutic use , Cardiovascular Diseases/prevention & control , Child , Colchicine/therapeutic use , Coronary Disease/prevention & control , Diet/adverse effects , Eczema/etiology , Female , Fish Oils/therapeutic use , Folic Acid/therapeutic use , Food Hypersensitivity , Gold/therapeutic use , Gout/drug therapy , Humans , Hypoglycemia/etiology , Magnesium/therapeutic use , Sleep/drug effects , Tryptophan/pharmacology , Uterine Cervical Dysplasia/drug therapyABSTRACT
This statement is an update of the 1970 Inter -Society Commission for Heart Disease Resources (ICHD) report, Primary Prevention of the Atherosclerotic Diseases. The charge to the Study Group was to assess relevant new data and, where the evidence is less than definitive, to formulate conclusions and recommendations based on best judgment. Current developments are reviewed, and issues raised in response to the earlier recommendations are considered. Recommendations are intended to serve as a guide for individual behavior, physician practice, and the formulation of public health policy.
Subject(s)
Arteriosclerosis/prevention & control , Bibliographies as Topic , Adult , American Heart Association , Arteriosclerosis/blood , Arteriosclerosis/etiology , Blood Pressure , Cardiovascular Diseases/mortality , Child , Coronary Disease/blood , Coronary Disease/etiology , Diabetes Complications , Diet/adverse effects , Female , Humans , Life Style , Male , Risk , United StatesABSTRACT
This statement is an update of the 1970 Inter-Society Commission for Heart Disease Resources ( ICHD ) report, "Primary Prevention of the Atherosclerotic Diseases." The charge to the Study Group was to assess relevant new data and, where the evidence is less than definitive, to formulate conclusions and recommendations based on best judgment. Current developments are reviewed, and issues raised in response to the earlier recommendations are considered. Recommendations are intended to serve as a guide for individual behavior, physician practice, and the formulation of public health policy.
Subject(s)
Coronary Disease/prevention & control , Primary Prevention/trends , Alcohol Drinking , Blood Pressure , Coffee , Contraceptives, Oral/adverse effects , Coronary Disease/etiology , Coronary Disease/mortality , Diabetes Complications , Diet, Atherogenic , Dietary Fiber/administration & dosage , Female , Humans , Hypertension/etiology , Life Style , Lipoproteins/blood , Male , Menopause , Obesity/complications , Population Surveillance , Public Policy , Risk , Smoking Prevention , Sodium Chloride/administration & dosage , United StatesABSTRACT
Twenty subjects underwent a double-blind evaluation by analyzing six variables to determine if subcutaneous injection of the food extract neutralizing dose would protect subjects from reactions. Twelve subjects had four of the six variables neutralized 60% of the time following the food antigen neutralizing dose. The placebo trials neutralized four of six variables 15% of the time. The sign/symptom results show statistical significance favoring food extract neutralization over placebo. The remaining eight subjects had at least two of the six variables neutralized by the food extract up to 85% of the time. It appears that the phenomenon of subcutaneous food neutralization can be scientifically endorsed for clinical use in the treatment of food reactions.
